These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17110011)

  • 1. Use of long-acting injectable risperidone before and throughout pregnancy in schizophrenia.
    Kim SW; Kim KM; Kim JM; Shin IS; Shin HY; Yang SJ; Yoon JS
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):543-5. PubMed ID: 17110011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia.
    Bhanji NH; Chouinard G; Margolese HC
    Eur Neuropsychopharmacol; 2004 Mar; 14(2):87-92. PubMed ID: 15013023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical review of a long-acting, injectable formulation of risperidone.
    Knox ED; Stimmel GL
    Clin Ther; 2004 Dec; 26(12):1994-2002. PubMed ID: 15823763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Int Clin Psychopharmacol; 2008 Nov; 23(6):325-31. PubMed ID: 18854720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The first long-acting atypical antipsychotic: new milestone in the treatment of schizophrenia].
    Faludi G
    Neuropsychopharmacol Hung; 2005 Mar; 7(1):22-7. PubMed ID: 16167464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
    Vehof J; Postma MJ; Bruggeman R; De Jong-Van Den Berg LT; Van Den Berg PB; Stolk RP; Burger H
    J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience and management considerations with long-acting risperidone.
    Parellada E
    Curr Med Res Opin; 2006 Feb; 22(2):241-55. PubMed ID: 16466596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An atypical long-acting injectable antipsychotic: implications for pharmacotherapy of schizophrenia.
    Dursun S
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):3-4. PubMed ID: 16144780
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapeutic drug monitoring of patients on risperidone depot.
    Nesvåg R; Tanum L
    Nord J Psychiatry; 2005; 59(1):51-5. PubMed ID: 16195099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.
    Keith S
    Expert Rev Neurother; 2009 Jan; 9(1):9-31. PubMed ID: 19102665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics.
    Ereshefsky L; Mascarenas CA
    J Clin Psychiatry; 2003; 64 Suppl 16():18-23. PubMed ID: 14680415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacoeconomic review of the use of injectable long-acting risperidone].
    Bartkó G; Fehér L
    Neuropsychopharmacol Hung; 2005 Dec; 7(4):199-207. PubMed ID: 16496485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients.
    Thyssen A; Rusch S; Herben V; Quiroz J; Mannaert E
    J Clin Pharmacol; 2010 Sep; 50(9):1011-21. PubMed ID: 20097933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
    Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
    Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness.
    Lasser RA; Bossie CA; Zhu Y; Locklear JC; Kane JM
    Ann Clin Psychiatry; 2007; 19(2):65-71. PubMed ID: 17612845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
    Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
    Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
    Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
    Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical guidelines: Dosing and switching strategies for long-acting risperidone.
    Marder SR; Conley R; Ereshefsky L; Kane JM; Turner MS
    J Clin Psychiatry; 2003; 64 Suppl 16():41-6. PubMed ID: 14680418
    [No Abstract]   [Full Text] [Related]  

  • 20. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.